Page 27 - Read Online

Oiseth et al. Cancer immunotherapy

treatment of patients with osteosarcoma. Ther Clin Risk Manag Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L.
2010;6:279-86. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential
43. Gardner TA, Elzey BD, Hahn NM. Sipuleucel-T (Provenge) mechanism of immune evasion. Nat Med 2002;8:793-800.
autologous vaccine approved for treatment of men with asymptomatic 65. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H,
or minimally symptomatic castrate-resistant metastatic prostate Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L,
cancer. Hum Vaccin Immunother 2012;8:534-9. Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR,
44. Kaiser J. Personalized tumor vaccines keep cancer in check. Science Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a
2017;356:122. novel B7 family member leads to negative regulation of lymphocyte
45. Speil C, Rzepka R. Vaccines and vaccine adjuvants as biological activation. J Exp Med 2000;192:1027-34.
response modifiers. Infect Dis Clin North Am 2011;25:755-72. 66. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M,
46. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA,
cancer. Res Rep Urol 2015;7:65-79. Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N,
47. Choi AH, O’Leary MP, Fong Y, Chen NG. From benchtop to bedside: Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is
a review of oncolytic virotherapy. Biomedicines 2016;4:E18. a second ligand for PD-1 and inhibits T cell activation. Nat Immunol
48. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells 2001;2:261-8.
in cancer immunotherapy. Nat Immunol 2016;17:1025-36. 67. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities,
49. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier differences, and implications of their inhibition. Am J Clin Oncol
E. A programmable dual-RNA-guided DNA endonuclease in adaptive 2016;39:98-106.
bacterial immunity. Science 2012;337:816-21. 68. Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford
50. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE,
X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering McClanahan T. PD-L2 expression in human tumors: relevance to
using CRISPR/Cas systems. Science 2013;339:819-23. Anti-PD-1 therapy in cancer. Clin Cancer Res 2017;23:3158-67.
51. Cyranoski D. CRISPR gene-editing tested in a person for the first 69. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and
time. Nature 2016;539:479. autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev
52. Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, Johnson B, Cuia W. 2008;224:166-82.
Pathogen boosted adoptive cell transfer immunotherapy to treat solid 70. Pardoll DM. The blockade of immune checkpoints in cancer
tumors. Proc Natl Acad Sci U S A 2017;114:740-5. immunotherapy. Nat Rev Cancer 2012;12:252-64.
53. Offord C. Making car T-cell therapy safer. The Scientist 2017; April 71. Chen DS, Mellman I. Oncology meets immunology: the cancer-
1. Available from: http://www.the-scientist.com/?articles.view/ immunity cycle. Immunity 2013;39:1-10.
articleNo/48973/title/Making-CAR-T-Cell-Therapy-Safer/. [Last 72. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor
accessed on 30 Oct 2017] immunity by CTLA-4 blockade. Science 1996;271:1734-6.
54. FDA News Release. FDA approval brings first gene therapy to the 73. Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1)
United States. Available from: https://www.fda.gov/NewsEvents/ expression by immunohistochemistry: could it be predictive and/
Newsroom/PressAnnouncements/ucm574058.htm. [Last accessed on or prognostic in non-small cell lung cancer? Cancer Biol Med
30 Oct 2017] 2016;13:157-70.
55. Gallimore A, Glithero A, Godkin A, Tissot AC, Plückthun A, Elliott 74. Ritprajak P, Azuma M. IIntrinsic and extrinsic control of expression
T, Hengartner H, Zinkernagel R. Induction and exhaustion of of the immunoregulatory molecule PD-L1 in epithelial cells and
lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes squamous cell carcinoma. Oral Oncol 2015;51:221-8.
visualized using soluble tetrameric major histocompatibility complex 75. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin
class I-peptide complexes. J Exp Med 1998;187:1383-93. J, Jordan K, ESMO Committee. Management of toxicities from
56. Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: immunotherapy: ESMO Clinical Practice Guidelines for diagnosis,
from pathophysiological basics to tumor immunotherapy. Cell treatment and follow-up. Ann Oncol 2017;28:iv119-42.
Commun Signal 2017;15:1. 76. Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M,
57. Mognol GP, Spreafico R, Wong V, Scott-Browne JP, Togher S, Kiehl M, Schellongowski P; Intensive Care in Hematological and
Hoffmann A, Hogan PG, Rao A, Trifari S. Exhaustion-associated Oncological Patients (iCHOP) Collaborative Group. New drugs, new
regulatory regions in CD8+ tumor-infiltrating T cells. Proc Natl Acad toxicities: severe side effects of modern targeted and immunotherapy
Sci U S A 2017;114:E2776-85. of cancer and their management. Crit Care 2017;21:89.
58. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell 77. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel
exhaustion. Nat Rev Immunol 2015;15:486-99. F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S,
59. Schietinger A, Greenberg PD. Tolerance and exhaustion: defining François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot
mechanisms of T cell dysfunction. Trends Immunol 2014;35:51-60. JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A.
60. Tsai HF, Hsu PN. Cancer immunotherapy by targeting immune Management of immune checkpoint blockade dysimmune toxicities:
checkpoints: mechanism of T cell dysfunction in cancer immunity and a collaborative position paper. Ann Oncol 2016;27:559-74.
new therapeutic targets. J Biomed Sci 2017;24:35. 78. Michot M, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-
61. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei Vinay S, Berdelou A, Varga Bahleda AR, Hollebecque A, Massard
MG, Golstein P. A new member of the immunoglobulin superfamily— C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin
CTLA-4. Nature 1987;328:267-70. E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A,
62. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects Lambotte O. Immune-related adverse events with immune checkpoint
on the response of T cells to stimulation. J Exp Med 1995;182:459-65. blockade: a comprehensive review. Eur J Cancer 2016;54:139-48.
63. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD- 79. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud
1, a novel member of the immunoglobulin gene superfamily, upon A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B,
programmed cell death. EMBO J 1992;11:3887-95. Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou
64. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ October 31, 2017 259